12.07.2015 Views

first edition (1980) of the Orange Book - FDA Law Blog

first edition (1980) of the Orange Book - FDA Law Blog

first edition (1980) of the Orange Book - FDA Law Blog

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

B - Drug products that <strong>FDA</strong> does not at this time consider to be <strong>the</strong>rapeuticallyequivalent to o<strong>the</strong>r pharmaceutically equivalent products.Certain multisource drugs awearing on <strong>the</strong> List have beenclassified with .a "B" code for a variety <strong>of</strong> reasons. Those drugs thathave been identified ~ <strong>the</strong> agency as having potential or actual bioinequivalenceproblems and for which adequate studies denmstrating <strong>the</strong>bioequivalence <strong>of</strong> <strong>the</strong> particular product have not been submitted to <strong>FDA</strong>are classified in <strong>the</strong> "B" category. A "B" evaluatioo generally is aresult <strong>of</strong> known or potential problems with <strong>the</strong> specific dosage form forthose active ingredients for which no bioinequivalence problem has beenidentified by <strong>the</strong> agency. In additim, <strong>the</strong>re are currently a fewproducts for which <strong>the</strong> standards are inadequate or for which <strong>FDA</strong> hasinsufficient informatim at <strong>the</strong> present time to determine if <strong>the</strong>y are,<strong>the</strong>r apeu ticall y equivalent.The specific coding definitions and };X>licies for <strong>the</strong> "B" sub-codesare as folloos:BeControlled Release Tablets, Capsules, and InjectablesThese dosage forms are subject to bioavailability andbioequivalence differences, primarily because differentfirms developing controlled release products for <strong>the</strong> sameactive ingredient rarely employ <strong>the</strong> same approach t<strong>of</strong>ormulating <strong>the</strong>ir controlled release products. <strong>FDA</strong>,<strong>the</strong>refore, does not evaluate different controlled releasedosage forms containing <strong>the</strong> same active ingredient inequal strength as bioequi valent unless equi valencebetween individual products has been specifically dernoostratedthrough appropriate bioequivalence studies.Controlled release products for which bioequivalence dataare available have been coded AB.BDActive Ingredient and/or Dosage Forms with DocumentedBioinequivalence ProblemsThe BD code denotes products containing activeingredlents wi th kno.vn bioinequi valence problems, and forwhich adequate studies have not been sutmitted to <strong>FDA</strong>demonstrating <strong>the</strong> bioequivalence <strong>of</strong> <strong>the</strong> drug products.Where such studies are available, <strong>the</strong> product has beencoded AB.I - 14

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!